Dendreon Corporation (NASDAQNDN) announced restructuring plans, overall cost reductions, and an update on PROVENGE® (sipuleucel-T) sales. Dendreon reported August gross revenues of approximately $22 million. Dendreon continues to expect modest quarter-over-quarter growth as it works to educate physicians on the improved reimbursement paradigm under the Centers for Medicaid and Medicare Services (CMS) recently established National Coverage Decision (NCD) and issuance of a product specific Q-code.

Read more at http://crwefinance.com/?p=20412